Journal of Clinical Trials

Journal of Clinical Trials
Open Access

ISSN: 2167-0870

Journal of Clinical Trials : Citations & Metrics Report

Articles published in Journal of Clinical Trials have been cited by esteemed scholars and scientists all around the world. Journal of Clinical Trials has got h-index 19, which means every article in Journal of Clinical Trials has got 19 average citations.

Following are the list of articles that have cited the articles published in Journal of Clinical Trials.

  2021 2020 2019 2018 2017

Year wise published articles

79 78 38 20 35

Year wise citations received

171 166 120 127 143
Journal total citations count 1444
Journal impact factor 2.76
Journal 5 years impact factor 3.07
Journal cite score 3.14
Journal h-index 19
Journal h-index since 2018 16
Important citations (609)

Frail older adults’ experience of participating in clinical trials

Revealing the impact of loss : exploring mental health through the use of drawing/writing with hiv positive adolescents in johannesburg

Effect of a planned training session on good clinical practice knowledge in research professionals: a pilot study

Predictive performance of gentamicin dosing nomograms

Reticence in disclosure of hiv infection and reasons for bereavement: impact on perinatally infected adolescents’ mental health and understanding of hiv treatment and prevention in johannesburg, south africa

Artificial intelligence based clinical data management systems: a review

Flow mediated dilation with photoplethysmography as a substitute for ultrasonic imaging

Dysphagia in multiple sclerosis: evaluation and validation of the dymus questionnaire

To be hiv positive is not the end of the world”: resilience among perinatally infected hiv positive adolescents in johannesburg

The frequency of dysphagia and its impact on adults with multiple sclerosis based on patient-reported questionnaires

Establishing short bowel syndrome in nigerian dogs

Methods to profile protien kinase substrates in cells

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a phase ii, single-arm, multicenter study

Therapeutic implications of the molecular and immune landscape of triple-negative breast cancer

Meeting the needs of breast cancer: a nucleolin’s perspective

Heterogeneous distribution of trastuzumab in her2-positive xenografts and metastases: role of the tumor microenvironment

Current approaches and emerging directions in her2-resistant breast cancer

Molecular characterization and targeted therapeutic approaches in breast cancer

Emerging concepts and designing effectiveness research in the process of care of patients hospitalized with an uncomplicated acute coronary syndrome

Qualitative study of community pharmacists’ and general practitioners’ views toward pharmacovigilance in lithuania